1 Ocak 2011 Dergi makalesi Açık Erişim

Alicikus, Zumre A.; Yamada, Yoshiya; Zhang, Zhigang; Pei, Xin; Hunt, Margie; Kollmeier, Marisa; Cox, Brett; Zelefsky, Michael J.

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/21197</identifier>
  <creators>
    <creator>
      <creatorName>Alicikus, Zumre A.</creatorName>
      <givenName>Zumre A.</givenName>
      <familyName>Alicikus</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Yamada, Yoshiya</creatorName>
      <givenName>Yoshiya</givenName>
      <familyName>Yamada</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Zhang, Zhigang</creatorName>
      <givenName>Zhigang</givenName>
      <familyName>Zhang</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Epidemiol &amp; Biostat, New York, NY 10021 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Pei, Xin</creatorName>
      <givenName>Xin</givenName>
      <familyName>Pei</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Hunt, Margie</creatorName>
      <givenName>Margie</givenName>
      <familyName>Hunt</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Kollmeier, Marisa</creatorName>
      <givenName>Marisa</givenName>
      <familyName>Kollmeier</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Cox, Brett</creatorName>
      <givenName>Brett</givenName>
      <familyName>Cox</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Zelefsky, Michael J.</creatorName>
      <givenName>Michael J.</givenName>
      <familyName>Zelefsky</familyName>
      <affiliation>Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Ten-Year Outcomes Of High-Dose, Intensity-Modulated Radiotherapy For Localized Prostate Cancer</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2011</publicationYear>
  <dates>
    <date dateType="Issued">2011-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/21197</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1002/cncr.25467</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">BACKGROUND. The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer. METHODS. Between April 1996 and January 1998, 170 patients received 81 gray (Gy) using a 5-field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network-defined risk groups. Toxicity data were scored according to the Common Terminology Criteria for Adverse Events Version 3.0. Freedom from biochemical relapse, distant metastases, and cause-specific survival outcomes were calculated. The median follow-up was 99 months. RESULTS. The 10-year actuarial prostate-specific antigen relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group; the 10-year distant metastases-free rates were 100%, 94%, and 90%, respectively; and the 10-year cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary toxicity was 11% and 5%, respectively; and the 10-year likelihood of developing grade 2 and 3 late gastrointestinal toxicity was 2% and 1%, respectively. No grade 4 toxicities were observed. CONCLUSIONS. To the authors' knowledge, this report represents the longest followed cohort of patients who received high-dose radiation levels of 81 Gy using IMRT for localized prostate cancer. The findings indicated that high-dose IMRT is well tolerated and is associated with excellent long-term tumor-control outcomes in patients with localized prostate cancer Cancer 2011; 117: 1429-37. (C) 2010 American Cancer Society.</description>
  </descriptions>
</resource>